One Nucleus and GTM Global Enter into Collaboration to Support Member International and Connectivity
Cambridge and London, UK, 05 September 2023
One Nucleus, the leading Life Science membership group supporting the translation of bio-innovation into successful businesses and ultimately patient benefit is delighted to announce the collaborative partnership with GTM Global (GTM), the unique online interactive ecosystem that engages with ambitious tech and digital scale-up businesses to expand internationally.
One Nucleus members will be able access GTM’s high-touch programme of…
One Nucleus and GTM Global Enter into Collaboration to Support Member International and Connectivity
Sign up to receive the latest regulatory updates from Boyds: https://boydconsultants.com/sign-up/
In this month's newsletter they shared recent guidance and key updates from the regulatory agencies:
Food and Drug Association (FDA)
European Medicines Agency (EMA)
Medicines and Healthcare products Regulatory Agency (MHRA)
European Commission (EC)
World Health Organisation (WHO)
On 5 October, Boyds is hosting a free webinar on 'How to successfully operationalize real-world data collection alongside expanded access programs', for more info and how to sign up, click here.
More than half the Cambridge startups [60.7%] listed in Seedtable’s ‘Startups in Cambridge to Watch’ list last month [July 2023] have already appeared on cofinitive’s #21toWatch list in previous years.
This timely revelation, as the nominations window for #21toWatch 2024 opens, confirms that the #21toWatch awards really do spotlight the brightest and best from across Cambridge and beyond.
#21toWatch recognises the outstanding people, companies and innovations in our region, providing high-level exposure and increasing opportunities for funding and investment for the winning candidates.
Every…
Check out and subscribe to the latest newsletter from Stevenage Bioscience Catalyst.
Highlights include:
UBS Asset Management and Reef Group secure approval for one of Europe's largest Life Sciences campuses in Europe
Cell and Gene Therapy, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapies
Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogenic cell immunotherapies
BioWednesday Stevenage: 6 September
In the latest edition of the Penningtons Manches Cooper LLP BioBrief newsletter, their team explores university-generated IP and in particular what it means for students who are involved and contributing to such IP...
Read more.
Lab-on-chip technology for screening live tumor
Glasgow, UK based – ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies on live tissue samples.
Combining the latest advances in microfluidics and 3D cell culture – ScreenIn3D’s unique chip technology enables researchers to use as few as 1000 cells for tens of 3D cancer screening experiments. ScreenIn3D has recently secured investment…
Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr. Tomasz Kostrzewski as Chief Scientific Officer. Previously Vice President of Science and Technology, Dr. Kostrzewski’s promotion creates a new position in CN Bio’s leadership team, marking another key milestone in the Company’s development as the fourth leadership-level appointment within the past year.
Dr. Kostrzewski has more than 15 years of experience in molecular and cellular biology…
Cambridge, UK / Waltham, MA, August 28, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher’) will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).
The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors.
Founded in 1998 and…
Oxford, UK - British techbio innovator Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI.
The company’s lead therapeutic programme, ETC-101, is the world’s first AI-designed bispecific T cell engager. It targets PRAME, a validated antigen present in many cancers but absent from healthy tissue.
The lead asset currently demonstrates single digit picomolar affinity – a million-fold higher affinity than the native receptor – with no known cross-reactivity…
Babraham Research Campus and Global proptech leader Equiem have announced a partnership that will provide an enhanced experience for the Campus’s life science community in Cambridge. The collaboration will create one central communication hub that will add value to the service offering for Babraham Research Campus companies and enhance the overall experience of life on Campus.
Occupiers will have access to the Equiem One platform where they can contribute their own content, and share news and company updates to promote their activities across the Campus community. The Equiem One platform…